This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
upcoming catalysts, and a balance sheet strong enough to fund years of development. For a time, the company looked like a high-upside growth stock. However, that story was put to the test in December, when Arcus announced the cancellation of its Phase 3 STAR-221 research due to inefficiency. While the stock is up 49% year-to-date (YTD), it has plunged 16% from its 52-week high of $26.40. So, has this setback weakened the investment case for Arcus, or does it signal that Arcus' path forward has been sharpened? Here's how investors should think about the stock now. While AI Panic Struck Applied Digital (APLD) Stock, the Smart Money Has a Different View JPMorgan Says to Sell NVDA March $160 Puts. Should You Actually? Should You Buy Micron Stock Before December 17? This Analyst Thinks So. Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Valu
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]Seeking Alpha
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RCUS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- RCUS's page on the SEC website